Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Beta thalassemia is described in the packet as a condition characterized by reduced (beta-plus) or absent (beta-zero) synthesis of the beta globin chains of hemoglobin. According to GeneReviews, it has two clinically significant forms, beta thalassemia major and beta thalassemia intermedia, caused by absent or reduced synthesis of the hemoglobin subunit beta. Listed synonyms include thalassemia major, beta thalassemia intermedia, and beta thalassemia minor. Orphanet-derived prevalence data in the packet place the condition in the rare category, at an estimated 1 to 9 per 1,000,000 people. GeneReviews describes the condition as more prevalent in populations from the Mediterranean, the Middle East, Central and Southeast Asia, and the Indian subcontinent, and also common in populations of African descent. It attributes the regional distribution most likely to selective pressure from malaria, and notes that, because of population migration, the condition can be found around the world.
GeneReviews describes individuals with beta thalassemia major as usually coming to medical attention within the first two years of life, with clinical presentation between ages six and 24 months. Affected infants show progressive pallor, poor weight gain, and stunted growth. Feeding problems, diarrhea, irritability, recurrent fever, and progressive enlargement of the abdomen caused by hepatosplenomegaly may occur. Individuals with beta thalassemia intermedia are described as having a more variable age of presentation owing to milder anemia that does not require regular red blood cell transfusions from early childhood. GeneReviews lists complications of iron overload that include stunted growth and failure of sexual maturation in children, and, in adults, involvement of the heart (arrhythmias, dilated cardiomyopathy), the liver (fibrosis and cirrhosis), and endocrine glands (resulting in diabetes mellitus and insufficiency of the parathyroid, thyroid, pituitary, and, less commonly, adrenal glands). Other possible complications listed include hypersplenism, transfusion-acquired infections, venous thrombosis (especially after splenectomy), pigment gallstones, and osteoporosis in adults. Complications of iron chelation therapy listed include ocular toxicity, hearing loss, liver injury, proteinuria, and agranulocytosis, several tied to specific chelating agents.
The packet lists no associated genes in its structured gene field. GeneReviews describes the condition as arising from pathogenic variants in the beta globin gene. Variants that abolish beta globin production are termed beta-zero, and biallelic beta-zero variants typically result in beta thalassemia major. Variants that reduce production are termed beta-plus; biallelic beta-plus variants can be associated with beta thalassemia intermedia or minor, and beta-plus variants combined with a beta-zero variant can be associated with beta thalassemia major. Some beta-plus variants are classified as mild or silent. GeneReviews states that clinical severity depends on the extent of imbalance between alpha and non-alpha globin chains, because unassembled alpha chains form inclusions that damage erythroid precursors in the bone marrow and spleen and cause ineffective erythropoiesis. GeneReviews describes beta thalassemia major and intermedia as inherited in an autosomal recessive manner, and states that parents of an affected individual are typically heterozygous carriers, who are typically clinically asymptomatic but have microcytosis and either mild anemia or no anemia.
According to GeneReviews, beta thalassemia major is suspected in an infant or child younger than two years with pallor, poor weight gain, stunted growth, mild jaundice, or hepatosplenomegaly, together with laboratory findings. These include reduced or absent hemoglobin A on newborn screening, increased hemoglobin A2 with or without increased hemoglobin F on hemoglobin electrophoresis, absence of iron deficiency, and severe microcytic hypochromic anemia with anisopoikilocytosis and nucleated red blood cells on peripheral blood smear. Beta thalassemia intermedia is suspected in individuals who present after age two years or with less severe but similar findings. GeneReviews states that in a proband older than 12 months the diagnosis is established by microcytic hypochromic anemia, absence of iron deficiency, characteristic blood smear findings, and decreased or absent hemoglobin A with increased hemoglobin A2 on hemoglobin analysis. In a proband younger than 12 months, the diagnosis is established by complete absence of hemoglobin A on newborn screening, which is diagnostic of beta-zero thalassemia, or by biallelic pathogenic or likely pathogenic variants with suggestive laboratory findings. GeneReviews states that molecular genetic testing is required for beta-plus thalassemia in infants younger than 12 months, and that biallelic variants of uncertain significance neither establish nor rule out the diagnosis. The differential diagnosis discussed includes sideroblastic anemias, congenital dyserythropoietic anemias, and severe iron deficiency.
The packet's orphan drug records list designations or withdrawn designations for arginine butyrate, isobutyramide, 2 dimethylbutyrate, sotatercept, and a CRISPR/Cas12a-edited autologous CD34+ cell product; none carries an approved status in the packet, and an orphan designation is not an approval. The sections below reflect GeneReviews. For beta thalassemia major, GeneReviews describes hematopoietic stem cell transplant as an alternative to red blood cell transfusions and iron chelation therapy, with an HLA-matched sibling as the ideal donor. It reports that outcomes relate to pretransplant clinical manifestations, with disease-free survival above 90% in children lacking pretransplant risk factors, a two-year overall survival of 80% and event-free survival of 76% in adults, and severe acute graft-versus-host disease in 9% of individuals. Cord blood transplantation is described as an alternative. GeneReviews also describes gene therapy as an emerging alternative: betibeglogene autotemcel, a lentiviral gene addition approach, with transfusion independence reported in 91% of individuals who are not homozygous for beta-zero alleles, and exagamglogene autotemcel, a CRISPR-based approach that induces gamma globin production. GeneReviews describes both products as approved by the FDA, but the packet's structured FDA records contain no verified approval status for them. Evaluations described after diagnosis include hemoglobin electrophoresis, molecular analysis of globin genotype, and genetic counseling by genetics professionals.
GeneReviews states that the prognosis in beta thalassemia major has improved dramatically over past decades, attributing this to noninvasive measurement of liver and cardiac iron accumulation, improved iron chelators, and decreased infection risk from transfusions. After 2000 these developments were associated with a significant decrease in cardiac mortality, previously reported to account for 71% of deaths. GeneReviews reports that life expectancy remains greatly diminished in low-resource settings, where more than half of individuals die before age 30 years, compared with more than half of individuals living to age 60 years in high-resource settings. If the diagnosis is established by age 24 months and transfusions maintaining a minimum hemoglobin concentration are started, growth and development are described as progressing normally until at least age ten to 11 years, after which severe iron overload complications are described as a risk.
ClinicalTrials.gov records in the packet include multiple active studies related to beta thalassemia and neighboring conditions. Examples include a Phase 3 study of danazol, prednisolone, and thalidomide combination therapy in thalidomide-refractory transfusion-dependent beta thalassemia (NCT07884773, recruiting), a Phase 4 study of luspatercept in India (NCT05891249, active, not recruiting), and a nonmyeloablative transplantation study for sickle cell disease and beta thalassemia (NCT02105766, active, not recruiting). Other records address growth evaluation in children and biospecimen collection for globin variants. Intervention types include drug therapy, biologic therapy, gene therapy, and other interventions. GeneReviews describes therapies under investigation that include approaches targeting iron dysregulation and a pyruvate kinase activator, and reports that preliminary results for one zinc finger nuclease approach were disappointing.
Data assembled from 6 of 12 sources · Last updated Nov 17, 2026, 3:52 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
50 trials found
AI-curated news mentioning beta thalassemia
Updated Feb 13, 2026
Vertex Pharmaceuticals and CRISPR Therapeutics project that revenues from Casgevy, a gene therapy for sickle cell disease and beta thalassemia, will nearly triple by 2026 as patient access improves. This ambitious goal follows a year of slow uptake for the therapy.